Archive for March, 2015

A new technology called CRISPR could allow scientists to alter the human genetic code for generations. That's causing some leading biologists and bioethicists to sound an alarm. They're calling for a worldwide moratorium on any attempts to alter the code, at least until there's been time for far more research and discussion.

It's not new that scientists can manipulate human DNA genetic engineering, or gene editing, has been around for decades. But it's been hard, slow and very expensive. And only highly skilled geneticists could do it.

Recently that's changed. Scientists have developed new techniques that have sped up the process and, at the same time, made it a lot cheaper to make very precise changes in DNA.

There are a couple of different techniques, but the one most often talked about is CRISPR, which stands for clustered regularly interspaced short palindromic repeats. My colleague Joe Palca described the technique for Shots readers last June.

Why scientists are nervous

On the one hand, scientists are excited about these techniques because they may let them do good things, such as discovering important principles about biology. It might even lead to cures for diseases.

The big worry is that CRISPR and other techniques will be used to perform germline genetic modification.

Basically, that means making genetic changes in a human egg, sperm or embryo.

Those kinds of changes would be passed down for generations. And that's something that's always been considered taboo in science.

One major reason that it's considered off limits, ethically, is that the technology is still so new that scientists really don't know how well it works.

View post:
Scientists Urge Temporary Moratorium On Human Genome Edits

Here's the classic, if overly simplistic, example: Children inherit sets of chromosomes from each of their parents, with each chromosome containing the genes for various traits. A blue-eyed child has to inherit the blue-eyed gene from both the mother and the father. Otherwise, the dominant brown-eyed gene trumps the recessive blue-eyed gene.

In reality, eye color is determined by more than one gene. But the same principle applies to genetic defects such as muscular dystrophy: Even if you inherit the mutated gene for muscular dystrophy from one parent, the normal gene from the other parent can compensate and keep you from getting the disease.

More from NBC News: ISIS is rich, but spending money fast There's no honeymoon start to this 2016 campaign Prize-linked savings: You can bank on winning this contest

The downside for genetic engineers is that the mechanism makes it harder to introduce desired mutations. Mutagenic chain reaction, or MCR, makes the job easier. The researchers behind the Science study tweaked the CRISPR genome-editing procedure in fruit flies to make a mutation that's generated on one copy of a chromosome spread automatically to the other copy. Thus, both copies of the gene carry the mutation.

"MCR is remarkably active in all cells of the body, with one result being that such mutations are transmitted to offspring via the germline with 95 percent efficiency," study lead author Valentino Gantz, a graduate student at the University of California at San Diego, said in a news release.

See the original post here:
New procedure for reliable gene editing

How to get the right treatment to the right patient at the right time

University of Glasgow leads the way in new global drug treatments

The University of Glasgow is launching the first ever Masters programme designed to specifically address the new paradigm in drug discovery stratified medicine which tailors drug therapies to individual patients genetic makeup.

The University of Glasgow is at the forefront of stratified medicine, which involves examining the genetic makeup of patients and their differing responses to drugs designed to treat specific diseases the right treatment to the right patient at the right time.

The course director of the new MSc in Clinical Trials and Stratified Medicine, Professor Matthew Walters, said: Stratified Medicine holds huge potential in the timely development of new treatments for human disease. It is among the most important concepts to emerge in 21stcentury clinical science and will be a crucial component of the global drive to increase the efficacy, safety and cost-effectiveness of new treatments.

He added: There has been global recognition of the need for training in this area so that we have young drug researchers in academia and the commercial environment imbued with the skills required to apply the science for the benefit of patients.

Glasgow is also home to the Stratified Medicine Scotland Innovation Centre, which combines cutting-edge genetic research with state-of-the-art health informatics and imaging technologies. It is a unique collaboration in healthcare between partners from academia, the NHS and the pharmaceutical industry.

There is already huge interest in stratified medicine and pharmaceutical science in Saudi Arabia, said Professor Walters.

China also has a nascent clinical trials industry and Professor Walters is keen to involve Chinese students and academics in this area.

One of the elements we need to be clear about is whether medicines have the same impact across different populations. People handle drugs differently in different parts of the globe. There will be a significant need for people in China with these skills to be running clinical trials over the next few decades, he said.

Read more here:
University of Glasgow leads the way in drug treatments

Photo: Andrew Brookes/Corbis

In 2005, next-generation sequencing began to change the field of genetics research. Obtaining a persons entire genome became fast and relatively cheap. Databases of genetic information were growing by the terabyte, and doctors and researchers were in desperate need of a way to efficiently sift through the information for the cause of a particular disorder or for clues to how patients might respond to treatment.

Companies have sprung up over the past five years that are vying to produce the first DNA search engine. All of them have different tacticssome even have their own proprietary databases of genetic informationbut most are working to link enough genetic databases so that users can quickly identify a huge variety of mutations. Most companies also craft search algorithms to supplement the genetic information with relevant biomedical literature. But as in the days of the early Web, before Google reigned supreme, a single company has yet to emerge as the clear winner.

Making a functional search engine is a classic big-data problem, says Michael Gonzalez, the vice president of bioinformatics at one such company, ViaGenetics, which was expected to relaunch its platform in March. Before doctors or researchers can use the data, genomic data must be organized so that humans can read and search it. The first step toward that is to put it in a standard form called the variant call format, or VCF. As raw data, a persons complete sequenced genome would take up about 100 gigabytes, so a database that adds the genomes of even 10 patients per day would quickly get out of hand. But VCF files are more compact, requiring only a few hundred megabytes per genome, which helps researchers find the specific variants they want to search in a fraction of the time. Unlike a fully sequenced genome, VCF files point only to where a persons genetic data deviates from the standardthe genome originally compiled by the Human Genome Project in 2001.

With VCF, sifting the genomes themselves for pinpoint mutations isnt the challenge for search engine companies. Most of these companies are allocating their resources toward efforts to seamlessly compile supplementary information about a specific mutation from other databases across the Web, such as the biomedical research archive PubMed or various troves of electronic medical records. Many of these tools have finely tuned algorithms that prioritize the results by credibility or relevance. You want to be able to pull together the information known about a mutation in that position [of the genome] and quickly make an assessment, says David Mittelman, the chief scientific officer for Tute Genomics, based in Provo, Utah, another company designing a genetic-search engine.

In an effort to expand the information that can be attached to a genome under examination, ViaGenetics, based in Miami Beach, Fla., is making its newly updated platform useful for researchers who want to collaborate across institutions. With ViaGenetics tools, researchers can make their data available to other users, so other people can come across these projects, request access, and form a collaboration, Gonzalez says. It helps people connect the dots between different researchers and institutions. This is especially helpful for smaller labs that may not have very extensive genome databases or for researchers from different universities working to decode the same mutation.

Although the genomic-search industry is now focused on serving scientists, that might not always be the case. Mittelman envisions that Tute Genomics could eventually serve consumers directly. People are already demanding information about their genomes just to understand themselves better, Mittelman says, but most companies dont yet consider the average person to be their primary customer. In order to make that shift, the tool will have to be even more intuitive and user-friendly. Fire-hosing someone with data thats not easy to interpret, or using terminology thats not standardized, has the potential to confuse people, he says. Privacy is also a major concern for the average user; the information that Tute users upload isnt stored permanently, Mittelman says, but users will need extra reassurance if the platform becomes available to the lay public.

And a further evolution of the industry is in the offing. Both ViaGenetics and Tute are hoping to be able to run the entire process in-housefrom the initial DNA sequencing to the presentation of final searchable results to users. The market for analyzing and interpreting genomic data is very fragmented, like the computer industry in the 1990s, where you had to go to separate providers to buy a video card or a motherboard and then try to put it together, Mittelman says. Soon this field will consolidate, as the computer industry did.

This article originally appeared in print as A Google for DNA.

See the original post here:
The Race to Build a Search Engine for Your DNA

A new study from Princeton University sheds light on the handing over of genetic control from mother to offspring early in development. Learning how organisms manage this transition could help researchers understand larger questions about how embryos regulate cell division and differentiation into new types of cells.

The study, published in the March 12 issue of the journal Cell, provides new insight into the mechanism for this genetic hand-off, which happens within hours of fertilization, when the newly fertilized egg is called a zygote.

"At the beginning, everything the embryo needs to survive is provided by mom, but eventually that stuff runs out, and the embryo needs to start making its own proteins and cellular machinery," said Princeton postdoctoral researcher in the Department of Molecular Biology and first author Shelby Blythe. "We wanted to find out what controls that transition."

Blythe conducted the study with senior author Eric Wieschaus, Princeton's Squibb Professor in Molecular Biology, Professor of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics, a Howard Hughes Medical Institute investigator, and a Nobel laureate in physiology or medicine.

Researchers have known that in most animals, a newly fertilized egg cell divides rapidly, producing exact copies of itself using gene products supplied by the mother. After a short while, this rapid cell division pauses, and when it restarts, the embryonic DNA takes control and the cells divide much more slowly, differentiating into new cell types that are needed for the body's organs and systems.

To find out what controls this maternal to zygotic transition, also called the midblastula transition (MBT), Blythe conducted experiments in the fruit fly Drosophila melanogaster, which has long served as a model for development in higher organisms including humans.

These experiments revealed that the slower cell division is a consequence of an upswing in DNA errors after the embryo's genes take over. Cell division slows down because the cell's DNA-copying machinery has to stop and wait until the damage is repaired.

Blythe found that it wasn't the overall amount of embryonic DNA that caused this increase in errors. Instead, his experiments indicated that the high error rate was due to molecules that bind to DNA to activate the reading, or "transcription," of the genes. These molecules stick to the DNA strands at thousands of sites and prevent the DNA copying machinery from working properly.

To discover this link between DNA errors and slower cell replication, Blythe used genetic techniques to create Drosophila embryos that were unable to repair DNA damage and typically died shortly after beginning to use their own genes. He then blocked the molecules that initiate the process of transcription of the zygotic genes, and found that the embryos survived, indicating that these molecules that bind to the DNA strands, called transcription factors, were triggering the DNA damage. He also discovered that a protein involved in responding to DNA damage, called Replication Protein A (RPA), appeared near the locations where DNA transcription was being initiated. "This provided evidence that the process of awakening the embryo's genome is deleterious for DNA replication," he said.

The study also demonstrates a mechanism by which the developing embryo ensures that cell division happens at a pace that is slow enough to allow the repair of damage to DNA during the switchover from maternal to zygotic gene expression. "For the first time we have a mechanistic foothold on how this process works," Blythe said.

Continued here:
Letting go of the (genetic) apron strings

Spring Fling Genetics Seminar AI Panel
The second session of the morning was the AI-Panel. It was made up of 6 past and present AI Sire Analysis #39;s. Roger Turned asked The group questions about how each of them work with breeders....

By: HolsteinWorld MOOTUBE

Here is the original post:
Spring Fling Genetics Seminar AI Panel - Video

*:Sims 4 Perfect Genetics Challenge Dey Getting Married Yo*: Ep8
Hi. I #39;m losingfireflies ( ) Marriage at it #39;s finest. I attempted to make a beautiful wedding anddddd it went okay.. ==================================== Social Media Twitte...

By: LosingFireflies

Go here to read the rest:
*:Sims 4 Perfect Genetics Challenge Dey Getting Married Yo*: Ep8 - Video

The Sims 3 - Perfect Genetics Challenge Ep.70 SEASON FINALE!
Come join me on my latest journey into the complex world of sims 3 genetics, as I try to get perfect foals and perfect children. Will I succeed in getting perfect genetics in both? Can I keep...

By: GamerGirlsNetwork

See the article here:
The Sims 3 - Perfect Genetics Challenge Ep.70 SEASON FINALE! - Video

The Genetics Of Spirit (Clip) - Sunday Conversations With Roy Masters
The Genetics Of Spirit (Clip) - From Sunday Conversation # 8608 - "Life and the Sin Factor" Recorded March 8th 2015 Watch On This Channel Or At https://www.fhu.com/sunday-conversations/#watch...

By: FHUDOTCOM

See the article here:
The Genetics Of Spirit (Clip) - Sunday Conversations With Roy Masters - Video

PLoS Genetics : Male-Biased Aganglionic Megacolon in the TashT Mouse Line Due to Perturbation...
Male-Biased Aganglionic Megacolon in the TashT Mouse Line Due to Perturbation of Silencer Elements in a Large Gene Desert of Chromosome 10. Karl-F. Bergeron et al (2015), PLoS Genetics ...

By: KeSimpulan

Follow this link:
PLoS Genetics : Male-Biased Aganglionic Megacolon in the TashT Mouse Line Due to Perturbation... - Video

Minute Genetics Project - Mutations are NOT all harmful
Mutations are often thought to be bad and causes diseases, however this is not always the case. We tackle the age old question of mutations in this semesters edition of Minute Genetics! The...

By: Faisal Adam

View original post here:
Minute Genetics Project - Mutations are NOT all harmful - Video

How to Personalize Your Nutrition Based On Genetics (Revised 3/19/15)
Sign-up for the weekly email newsletter and get a FREE PDF REPORT! http://www.foundmyfitness.com/?sendme=nutrigenomics (Report covers ALL of the information in this video, citations, and more....

By: FoundMyFitness

Go here to read the rest:
How to Personalize Your Nutrition Based On Genetics (Revised 3/19/15) - Video

The Sims 4 | Perfect Genetics Legacy | Part 26 - First Teenager
The first season of the Legacy Challenge is coming to an end with Get To Work coming in 11 DAYS!! This means it is time to start winding down getting the family prepared for the future. It...

By: Connor K Games

Read more from the original source:
The Sims 4 | Perfect Genetics Legacy | Part 26 - First Teenager - Video

Explaining gene therapy for wet AMD
Shows how wet macular degeneration destructs vision, how secretion gene therapy works and how people can benefit.

By: Elizabeth Rakoczy

More:
Explaining gene therapy for wet AMD - Video

Nobel Prize winners raise alarm over genetic engineering of humans.

A group of senior American scientists and ethics experts is calling for debate on the gene-engineering of humans, warning that technology able to change the DNA of future generations is now imminent.

In policy recommendations published today in the journal Science, eighteen researchers, including two Nobel Prize winners, say scientists should accept a self-imposed moratorium on any attempt to create genetically altered children until the safety and medical reasons for such a step can be better understood.

The concern is over a rapidly advancing gene-editing technology, called CRISPR-Cas9, which is giving scientists the ability to easily alter the genome of living cells and animals (see Genome Surgery). The same technology could let scientists correct DNA letters in a human embryo or egg cell, for instance to create children free of certain disease-causing genes, or perhaps with improved genetics.

What we are trying to do is to alert people to the fact that this is now easy, says David Baltimore, a Nobel Prize winner and former president of Caltech, and an author of the letter. We cant use the cover we did previously, which is that it was so difficult that no one was going to do it.

Many countries already ban germ line engineeringor changing genes in a way that would be heritable from one generation to the nextonethical or safety grounds. Others, like the U.S., have strict regulations that would delay the creation of gene-edited children for years, if not decades. But some countries have weak rules, or none at all, and Baltimore said a reason scientists were speaking publicly now was to keep people from doing anything crazy.

The advent of CRISPR is raising social questions of a kind not confronted since the 1970s, when the ability to change DNA in microrganisms was first developed. In a now famous meeting in 1975, in Asilomar, California, researchers agreed to avoid certain kinds of experiments that were then deemed dangerous. Baltimore, who was one of the organizers of the Asilomar meeting, says the scientists behind the letter want to offer similar guidance for gene-engineered babies.

The prospect of genetically modified humans is surprisingly close at hand. A year ago, Chinese researchers created monkeys whose DNA was edited using CRISPR (see 10 Breakthrough Technologies 2014: Genome Editing).

Since then,several teams of researchers in China, the U.S., and the U.K. have begun using CRISPR to change the DNA of human embryos, eggs, and sperm cells, with an eye toward applying the technology at in vitro fertility (IVF) clinics. That laboratory research was described by MIT Technology Review earlier this month (see Engineering the Perfect Baby).

Last week, in Nature, representatives of an industry group, the Alliance for Regenerative Medicine, recommended a wider moratorium that would also include a cessation of such laboratory studies, which it termed dangerous and ethically unacceptable (see Industry Body Calls for Gene-Editing Moratorium).

Read this article:
Scientists Call for a Summit on Gene-Edited Babies

Horizon Discovery: The Impact of Horizons Technology Platform (short version)
Horizon #39;s unique gene editing platform powers everything we do. Learn more about how it works, and why the models that are generated are so powerful, changing the way that drugs are being...

By: Horizon Discovery

See the rest here:
Horizon Discovery: The Impact of Horizons Technology Platform (short version) - Video

APOSEC in Stroke and Spinal Cord Injury
Beschreibung.

By: secretome regeneration

Original post:
APOSEC in Stroke and Spinal Cord Injury - Video

MIAMI (PRWEB) March 19, 2015

Global Stem Cells Group and its subsidiary, Stem Cells Training, has coordinated with Emil Arroyo, M.D. and Horacio Oliver, M.D. to conduct the first of four stem cell training courses planned for Bolivia in 2015. Devised to meet the increasing demand for regenerative medicine techniques in the region, the first adipose derived harvesting, isolation and re-integration training course will take place April 4 and 5, 2015, in Santa Cruz.

The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn the techniques in harvesting and reintegrating stem cells derived from adipose tissue and bone marrow. The objective of the training is to provide physicians with practical stem cell medicine techniques they can use in-office to treat a variety of conditions in their patients.

For more information, visit the Global Stem Cells Group website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

More:
Global Stem Cells Group to Hold Practical Adipose-Derived Stem Cell Harvesting, Isolation and Re-integration Training ...

Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM
http://r3stemcell.com/stem-cell-treatments/amniotic-derived-stem-cell-injections/ Amniotic derived stem cell therapy has become exceptionally popular due to the benefits that are being seen....

By: R3 Stem Cell

Excerpt from:
Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM - Video

The Alpha Clinic for Cell Therapy and Innovation | City of Hope
A new grant to City of Hope from the California Institute for Regenerative Medicine (CIRM) will make it possible for novel stem cell based therapies developed here at City of Hope to...

By: City of Hope

See original here:
The Alpha Clinic for Cell Therapy and Innovation | City of Hope - Video

A human embryonic stem cell line derived at Stanford University.(REUTERS/Julie Baker/Stanford University School of Medicine/California Institute for Regenerative Medicine/Handout)

Type 2 diabetes is marked by insulin resistance, or the bodys inability to store sugar and convert it into carbohydrates for energy. Overcoming that resistance is the main hurdle scientists face in creating new treatment for the condition, but researchers in Canada have found a promising means for doing so: combining stem cell therapy and antidiabetic medication.

Type 2 diabetes accounts for nearly 95 percent of the 400 million diabetes cases worldwide. Current treatment involves imprecise insulin injection, and can produce side effects like unwanted weight gain, gastrointestinal issues and low blood glucose levels. Eighty percent of Type 2 diabetes patients are overweight.

In the study, published Thursday in the journal Stem Cell Reports, scientists observed that transplanting human stem cells into mice with Type 2 diabetes symptoms, then administering common antidiabetic drugs, improved the mices glucose metabolism, body weight and insulin sensitivity three hallmark problems associated with the condition.

There have been similar reports looking at treatment of type 1 diabetes by stem cell-based replacement, and there are many people around the world who are interested in that, lead study author Timothy J. Kieffer, a molecular and cellular medicine professor at the University of British Columbia, in Vancouver, told FoxNews.com. Until this point, nobody to our knowledge had tested such a stem cell-based transplant study in a Type 2 diabetes model.

Many [of these studies] have been predicted to fail because one of the characteristics of Type 2 diabetes is insulin resistance, and that is in part due to obesity and higher demands of insulin, Kieffer added, and therefore it might be predicted that insulin replacement wouldnt work if were just putting insulin back.

Researchers fed four separate groups of immunosuppressed mice a different diet to try to emulate humans diagnosed with Type 2 diabetes. One group of mice received a 45 percent fat diet; one a 60 percent fat diet; one a high-fat, Western diet; and the last a low-fat diet. No single group of mice developed a phenotype that exactly mimicked a Type 2 diabetes human patient, but all three high-fat groups ended up exhibiting characteristics that mirrored the hallmark features of the condition.

Study authors transplanted human embryonic stem cell (hESC)-derived pancreatic progenitor cells into the mice after they began exhibiting symptoms. These cells are programmed to expand and differentiate when transplanted into the pancreas, and to subsequently secrete insulin.

To transplant the human stem cells, researchers used a macroencapsulation device, a mechanism that is meant to prevent the body from detecting nonnative material as foreign and subsequently rejecting it. Because the mice were immunosuppressed, the device wasnt necessary, but Kieffer said his team used it so their findings would be more relevant for future clinical trials, wherein the patients would not be immunosuppressed. Researchers opted to induce Type 2 diabetes symptoms in immunosuppressed mice instead of using the mice model genetically engineered to assume Type 2 diabetes for that same reason.

The hope in the field is that some sort of device will eliminate the need for immunosuppression when cells are transplanted, Kieffer said.

See the article here:
Stem cell therapy may help treat type 2 diabetes

Stoke Mandeville Spinal Research
Paralysis. Life. Each day, some people wake up having to think about both. That #39;s why, each day, Stoke Mandeville Spinal Research does the same, thinking long and hard about how we can make...

By: Stoke Mandeville Spinal Research

Go here to see the original:
Stoke Mandeville Spinal Research - Video

Foot and Ankle Injuries Treated with Prolotherapy
Are you suffering from chronic foot and ankle pain? We would love to help you. Prolotherapy is a regenerative injection treatment that stimulates the body to repair the painful areas. It is...

By: Caring Medical Regenerative Medicine Clinics

Originally posted here:
Foot and Ankle Injuries Treated with Prolotherapy - Video

Tennis Injuries Treated with Prolotherapy
Dr. Tim Speciale explains how Prolotherapy is a great option for tennis elbow and other sports injuries. If you would like an opinion on regenerative injection treatments, like Prolotherapy...

By: Caring Medical Regenerative Medicine Clinics

Link:
Tennis Injuries Treated with Prolotherapy - Video

Laurel Barchas: Becoming a Stem Cel Scientist
In this video produced by ConnectEd California, Laurel Barchas, a Ph.D. student in Integrative Biology at UC Berkeley, describes how her passion for stem cell research has inspired her to bring...

By: California Institute for Regenerative Medicine

Read more:
Laurel Barchas: Becoming a Stem Cel Scientist - Video